A citation-based method for searching scientific literature

Michael J Grant, Roy S Herbst, Sarah B Goldberg. Nat Rev Clin Oncol 2021
Times Cited: 7







List of co-cited articles
12 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
28

PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
28

NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes.
Anju Singh, Anneleen Daemen, Dorothee Nickles, Sang-Min Jeon, Oded Foreman, Kuladeep Sudini, Florian Gnad, Stephane Lajoie, Naina Gour, Wayne Mitzner,[...]. Clin Cancer Res 2021
20
28

ARID1A mutations and expression loss in non-small cell lung carcinomas: clinicopathologic and molecular analysis.
Yin P Hung, Amanda Redig, Jason L Hornick, Lynette M Sholl. Mod Pathol 2020
11
28

Clinicopathologic Characteristics of BRG1-Deficient NSCLC.
Ibiayi Dagogo-Jack, Alexa B Schrock, Marina Kem, Nicholas Jessop, Jessica Lee, Siraj M Ali, Jeffrey S Ross, Jochen K Lennerz, Alice T Shaw, Mari Mino-Kenudson. J Thorac Oncol 2020
24
28

SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
Joao V Alessi, Biagio Ricciuti, Liam F Spurr, Hersh Gupta, Yvonne Y Li, Carolyn Glass, Mizuki Nishino, Andrew D Cherniack, James Lindsay, Bijaya Sharma,[...]. J Thorac Oncol 2021
5
40

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.
Ming Sound Tsao, Keith M Kerr, Mark Kockx, Mary-Beth Beasley, Alain C Borczuk, Johan Botling, Lukas Bubendorf, Lucian Chirieac, Gang Chen, Teh-Ying Chou,[...]. J Thorac Oncol 2018
356
28

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, Matthew D Hellmann, Mark M Awad, Justin F Gainor, Alexa B Schrock, Ryan J Hartmaier, Sally E Trabucco, Laurie Gay,[...]. Cancer Discov 2018
552
28

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
Lynette M Sholl, Fred R Hirsch, David Hwang, Johan Botling, Fernando Lopez-Rios, Lukas Bubendorf, Mari Mino-Kenudson, Anja C Roden, Mary Beth Beasley, Alain Borczuk,[...]. J Thorac Oncol 2020
53
28

Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads.
Danielle M Lussier, Elise Alspach, Jeffrey P Ward, Alexander P Miceli, Daniele Runci, J Michael White, Cedric Mpoy, Cora D Arthur, Heather N Kohlmiller, Tyler Jacks,[...]. Proc Natl Acad Sci U S A 2021
5
40

The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer.
Adam J Schoenfeld, Chai Bandlamudi, Jessica A Lavery, Joseph Montecalvo, Azadeh Namakydoust, Hira Rizvi, Jacklynn Egger, Carla P Concepcion, Sonal Paul, Maria E Arcila,[...]. Clin Cancer Res 2020
30
28

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
D Marinelli, M Mazzotta, S Scalera, I Terrenato, F Sperati, L D'Ambrosio, M Pallocca, G Corleone, E Krasniqi, L Pizzuti,[...]. Ann Oncol 2020
42
28

Immunodeficiency caused by cirrhosis.
Ewelina Tuchendler, Paweł K Tuchendler, Grzegorz Madej. Clin Exp Hepatol 2018
8
14

Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Fumihiro Shoji, Hiroaki Takeoka, Yuka Kozuma, Gouji Toyokawa, Koji Yamazaki, Masao Ichiki, Sadanori Takeo. Lung Cancer 2019
35
14

A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.
Julien Edeline, Jean-Frédéric Blanc, Philip Johnson, Boris Campillo-Gimenez, Paul Ross, Yuk Ting Ma, Judy King, Richard A Hubner, Kate Sumpter, Suzanne Darby,[...]. Liver Int 2016
61
14

Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.
Philip J Johnson, Sarah Berhane, Chiaki Kagebayashi, Shinji Satomura, Mabel Teng, Helen L Reeves, James O'Beirne, Richard Fox, Anna Skowronska, Daniel Palmer,[...]. J Clin Oncol 2015
943
14

Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
Ryo Morita, Kyoichi Okishio, Junichi Shimizu, Haruhiro Saito, Hiroshi Sakai, Young Hak Kim, Osamu Hataji, Makiko Yomota, Makoto Nishio, Keisuke Aoe,[...]. Lung Cancer 2020
31
14


Monoclonal antibody pharmacokinetics and pharmacodynamics.
W Wang, E Q Wang, J P Balthasar. Clin Pharmacol Ther 2008
645
14

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
Michael A Postow, Robert Sidlow, Matthew D Hellmann. N Engl J Med 2018
14

Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy.
Kazuki Takada, Shinkichi Takamori, Yasuto Yoneshima, Kentaro Tanaka, Isamu Okamoto, Mototsugu Shimokawa, Taro Oba, Atsushi Osoegawa, Tetsuzo Tagawa, Mitsuhiro Takenoyama,[...]. Lung Cancer 2020
16
14


Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
14

Immune Checkpoint Blockade in Cancer Therapy.
Michael A Postow, Margaret K Callahan, Jedd D Wolchok. J Clin Oncol 2015
14

Are hepatic impairment studies necessary for therapeutic proteins?
Jun Yang, Stacy Shord, Hong Zhao, Yuxin Men, Atiqur Rahman. Clin Ther 2013
6
16

The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab.
Taichi Matsubara, Shinkichi Takamori, Naoki Haratake, Ryo Toyozawa, Naoko Miura, Mototsugu Shimokawa, Masafumi Yamaguchi, Takashi Seto, Mitsuhiro Takenoyama. J Thorac Dis 2020
17
14

Causes and Consequences of Innate Immune Dysfunction in Cirrhosis.
Katharine Margaret Irvine, Isanka Ratnasekera, Elizabeth E Powell, David Arthur Hume. Front Immunol 2019
44
14


Clinical Challenges of Immune Checkpoint Inhibitors.
Maria de Miguel, Emiliano Calvo. Cancer Cell 2020
42
14


Does Hepatic Impairment Affect the Exposure of Monoclonal Antibodies?
Qin Sun, Shirley Seo, Simbarashe Zvada, Chao Liu, Kellie Reynolds. Clin Pharmacol Ther 2020
7
14

Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study.
Takayuki Shiroyama, Izumi Nagatomo, Shohei Koyama, Haruhiko Hirata, Sumiyuki Nishida, Kotaro Miyake, Kiyoharu Fukushima, Yuya Shirai, Yuichi Mitsui, So Takata,[...]. Sci Rep 2019
58
14


Relationship between markers of malnutrition and clinical outcomes in older adults with cancer: systematic review, narrative synthesis and meta-analysis.
Alex F Bullock, Sarah L Greenley, Gordon A G McKenzie, Lewis W Paton, Miriam J Johnson. Eur J Clin Nutr 2020
14
14

Prognostic Impact of Albumin-bilirubin (ALBI) Grade on Non-small Lung Cell Carcinoma: A Propensity-score Matched Analysis.
Fumihiko Kinoshita, Takanori Yamashita, Yuka Oku, Keisuke Kosai, Yuki Ono, Sho Wakasu, Naoki Haratake, Gouji Toyokawa, Tomoyoshi Takenaka, Tetsuzo Tagawa,[...]. Anticancer Res 2021
1
100

CD8+T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction.
Fanny Lebossé, Cathrin Gudd, Enes Tunc, Arjuna Singanayagam, Rooshi Nathwani, Evangelos Triantafyllou, Oltin Pop, Naveenta Kumar, Sujit Mukherjee, Tie Zheng Hou,[...]. EBioMedicine 2019
22
14

Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn,[...]. N Engl J Med 2015
14

Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies.
Yasuto Yoneshima, Kentaro Tanaka, Yoshimasa Shiraishi, Kojiro Hata, Hiroyuki Watanabe, Taishi Harada, Kohei Otsubo, Eiji Iwama, Hiroyuki Inoue, Satohiro Masuda,[...]. Lung Cancer 2019
16
14

Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function.
Atsushi Hiraoka, Kojiro Michitaka, Takashi Kumada, Namiki Izumi, Masumi Kadoya, Norihiro Kokudo, Shoji Kubo, Yutaka Matsuyama, Osamu Nakashima, Michiie Sakamoto,[...]. Liver Cancer 2017
84
14

Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance.
Agustín Albillos, Margaret Lario, Melchor Álvarez-Mon. J Hepatol 2014
482
14

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
Lihong Peng, Yong Wang, Fen Liu, Xiaotong Qiu, Xinwei Zhang, Chen Fang, Xiaoyin Qian, Yong Li. Cancer Immunol Immunother 2020
24
14

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.
Ashley M Hopkins, Andrew Rowland, Ganessan Kichenadasse, Michael D Wiese, Howard Gurney, Ross A McKinnon, Chris S Karapetis, Michael J Sorich. Br J Cancer 2017
98
14

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade.
David J Pinato, Takahiro Kaneko, Anwaar Saeed, Tiziana Pressiani, Ahmed Kaseb, Yinghong Wang, David Szafron, Tomi Jun, Sirish Dharmapuri, Abdul Rafeh Naqash,[...]. Cancers (Basel) 2020
14
14

Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.
Benoît Roch, Amandine Coffy, Sandy Jean-Baptiste, Estelle Palaysi, Jean-Pierre Daures, Jean-Louis Pujol, Sébastien Bommart. Lung Cancer 2020
32
14

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Stefan Diem, Sabine Schmid, Mirjam Krapf, Lukas Flatz, Diana Born, Wolfram Jochum, Arnoud J Templeton, Martin Früh. Lung Cancer 2017
303
14


Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications.
Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo, Masashi Hirooka, Kunihiko Tsuji, Ei Itobayashi, Kazuya Kariyama, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi,[...]. Liver Cancer 2017
80
14

Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas.
Francois Ng Kee Kwong, Ute Laggner, Olivia McKinney, James Croud, Alexandra Rice, Andrew G Nicholson. Histopathology 2018
19
14

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.
Siwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, Tristan R Grogan, Hira Rizvi, Daniel K Wells, James Carroll, Amy Cummings, John Madrigal, Benjamin Jones,[...]. Clin Cancer Res 2019
30
14

Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.
Davis Y Torrejon, Gabriel Abril-Rodriguez, Ameya S Champhekar, Jennifer Tsoi, Katie M Campbell, Anusha Kalbasi, Giulia Parisi, Jesse M Zaretsky, Angel Garcia-Diaz, Cristina Puig-Saus,[...]. Cancer Discov 2020
23
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.